ScreenerHero
VCREVicore Pharma Holding AB American Depositary Shares
NAS · US · Healthcare · Biotechnology · vicorepharma.com
11.80USD-1.67%Mkt Cap: 337.83M $P/E: —

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap337.83M $
Enterprise Value—
Revenue (TTM)—
Gross Profit3.82M $
Net Income (TTM)-477.47M $
Revenue/Share—
Last Price11.80 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.94
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)-2.00
EPS (Forward)—
52W Range
11.791% of range12.50
52W High12.50 USD
52W Low11.79 USD
Profitability
Gross Margin100.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-12509.14%
ROE-43.59%
ROA-39.18%
Growth
Revenue Growth-32.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-375.74M $
CapEx (TTM)—
FCF Margin—
FCF Yield-71.63%
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio12.69
Quick Ratio12.57
Book Value/Sh—
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)35.32 USD
Upside (mean)+199.3%
Target Range35.32 USD – 35.32 USD
# Analysts1
Ownership
Shares Out.28.15M
Float198.62M
Insiders—
Institutions—
Short Interest
Short Ratio0.1d
Short % Out.0.05%
Shares Short16.12K
Technical
SMA 5012.26 (-3.8%)
SMA 20012.26 (-3.8%)
Beta0.12
S&P 52W Chg18.16%
Avg Vol (30d)8.99K
Avg Vol (10d)5.95K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—